Anti blood clotting drug Xarleto approved by FDA after lengthy approval process

J&J and Bayer stand to benefit from the FDA’s recent approval of the anticlotting drug.

The FDA is trying to be more responsive and quicker with it’s approval process.

Our take is that Xarleto because patients don’t like Coudmadin because it requires frequent monitoring

to ensure that the proper level of the drug is pleasant in the bloodstream.

The Xarleto dru will a welcome addition to the anticlotting class of drugs

Post a comment or leave a trackback: Trackback URL.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: